Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection
Publication Type:
Journal Article
Authors:
Fontana, Robert J.;
Brown, Robert S.;
Moreno-Zamora, Ana;
Prieto, Martin;
Joshi, Shobha;
Londoño, Maria-Carlota;
Herzer, Kerstin;
Chacko, Kristina R.;
Stauber, Rudolf E.;
Knop, Viola;
Jafri, Syed-Mohammed;
Castells, Lluís;
Ferenci, Peter;
Torti, Carlo;
Durand, Christine M.;
Loiacono, Laura;
Lionetti, Raffaella;
Bahirwani, Ranjeeta;
Weiland, Ola;
Mubarak, Abdullah;
ElSharkawy, Ahmed M.;
Stadler, Bernhard;
Montalbano, Marzia;
Berg, Christoph;
Pellicelli, Adriano M.;
Stenmark, Stephan;
Vekeman, Francis;
Ionescu-Ittu, Raluca;
Emond, Bruno;
Reddy, K. RajenderSource:
Liver Transpl, Volume 22, Issue 4, p.446-458 (2016)
Keywords:
Aged,
Antiviral Agents,
Compassionate Use Trials,
Drug Therapy, Combination,
Female,
Genotype,
Hepacivirus,
Hepatitis C, Chronic,
Humans,
Imidazoles,
Liver Cirrhosis,
Liver Diseases,
Liver Transplantation,
Male,
Middle Aged,
Recurrence,
Retrospective Studies,
Ribavirin,
simeprevir,
sofosbuvir,
Treatment Outcome
